Schizophrenia patient Marty Cohen joins psych LINK to share his perspective on his personal journey to recovery and reintegration. This activity was supported by an unrestricted educational grant from Eli Lilly and Company. Patients with psychosis and schizophrenia who respond poorly or exhibit a partial response to their treatment plan present an ongoing challenge to clinicians. Many patients on conventional antipsychotics continue to exhibit clinically significant symptoms including impaired impulse control, impaired frustration tolerance and emotional deregulation. Contributing to the poor response are the EPS and prolactin-related side effects of the conventional agents.
Atypical antipsychotics offer a more effective and better tolerated treatment option.
The psych LINK experts will examine the challenges presented by the partially responsive patient and discuss how atypical antipsychotics and non-pharmacologic management programs fit into the total treatment plan. This activity was supported by an unrestricted educational grant from AstraZeneca. For patients and their caregivers, AD is an intensely disturbing condition characterized by memory loss, cognitive deficits, and deterioration in the ability to perform daily activities. The psych LINK experts will explore the pathogenesis and diagnosis of AD and explore the role of cholinesterase inhibitors in improving patient outcomes. This activity was supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation.